Helping Kids with Crohn's

Traditional treatment for Crohn's disease -- a serious bowel disorder affecting more than 100,000 children in the U.S. -- carries side effects such as weight gain, acne, and depression. Researchers have turned to monoclonal antibodies, a new class of drugs that precisely target a protein in the body's immune system. Remicaid, one of the first such drugs to be approved by the FDA, attacks a protein produced by the immune system and known to cause gastrointestinal inflammation. Patients in a clinical study of Remicaid have experienced a 50 percent improvement after only 2 weeks.